Pediatric nephrology

ISN TrialWatch

Trialwatch
home

ISN TrialWatch | Jan – Feb – March 2026

IVIG Modulates Fibrosis and Stabilizes Chronic Active AMR Progression
This phase 2 randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of BI 764198, a selective oral inhibitor of the TRPC6 channel, in adults with biopsy-confirmed primary or TRPC6-related genetic focal segmental glomerulosclerosis (FSGS).
Trial of the month:

ISN TrialWatch | June – July 2025

Stronger Together: Finerenone & Empagliflozin Boost Kidney Outcomes in Diabetes
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes The CONFIDENCE trial was a double-blind, randomized study enrolling 800 participants with chronic kidney disease (CKD) (eGFR 30–90 ml/min/1.73 m²), albuminuria (urinary albumin-to-creatinine ratio [UACR] 100– 5000 mg/g), and type 2 diabetes, all of whom were receiving renin–angiotensin system inhibitors. Participants were randomly assigned in a 1:1:1 ratio to...
Trial of the month: